Cannacord rates Osprey Medical (OSP) a buy with a price target of $1.25 from the current price of around $.69. Osprey presented to a room of investors at a specialist Biotech event in Melbourne on Thursday and was a stand out story. In simple terms the Company is looking to prevent people with chronic kidney disease from suffering further damage when they go into hospital for treatment. Osprey's lead product, Avert, is well advanced and has a first mover advantage in this market. Avert is entering a critical phase with the commencement of a 700ncandidate patient trial and commercial discussions now commencing in the US. The technology has received strong endorsements to date and it is anticipated to move into commercial roll out towards the end of 2014. Osprey's MD Mr Mike McCormick talks through his vision and plans for the business.
Livewire Exclusive brings you exclusive content from a wide range of leading fund managers and investment professionals.